Heart-Safe breast cancer treatment shows promise in new trial
NCT ID NCT06845319
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a 12-18 week treatment without anthracyclines (a type of chemo that can harm the heart) for people with triple-negative breast cancer who already have heart conditions or are at high risk for heart damage. The treatment combines two chemotherapy drugs (carboplatin and paclitaxel) with an immunotherapy drug (pembrolizumab). The goal is to see if this approach can effectively shrink or eliminate tumors before surgery while being safer for the heart. About 43 participants will be enrolled.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Medical University of South Carolina
RECRUITINGCharleston, South Carolina, 29425, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new nucleotide analogue boost cancer treatment?
- Can a drug duo tame Triple-Negative breast cancer?
- Can a new drug ST316 shrink Hard-to-Treat tumors?
- Could a genetic marker guide future cancer therapies in taiwan?
- New drug targets Hard-to-Treat breast cancer in advanced stage
- New PET tracer could sharpen detection of aggressive breast cancer